Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Alpha-1 Adrenergic Antagonist (1) ·
Anxiolytic (1) ·
Benzodiazepine (1) ·
Beta Blocker (1) ·
Cardioselective (β1) + vasodilator (1) ·
Dual orexin receptor antagonist (DORA) (2) ·
Serotonin partial agonist reuptake inhibitor (SPARI) (1) ·
Triazolobenzodiazepine (1) ·
[[:Category:ACE_inhibitors|ACE inhibitor]] (1) ·
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (1) ·
[[:Category:Antianginals|Antianginal]] (1) ·
[[:Category:Antidepressants|Antidepressant]] (1) ·
[[:Category:Antiemetics|Antiemetic]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (3) ·
[[:Category:Anxiolytics|Anxiolytic]] (1) ·
[[:Category:Beta-3_agonists|β3 adrenergic agonist]] (1) ·
[[:Category:Calcium_channel_blockers|Calcium channel blocker]] (1) ·
[[:Category:Cholesterol_absorption_inhibitors|Cholesterol absorption inhibitor]] (1) ·
[[:Category:Dopamine_D2_antagonists|Dopamine D2 antagonist]] (1) ·
[[:Category:Heart_failure_medications|Heart failure medication]] (1) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (1) ·
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1) ·
[[:Category:Prokinetics|Prokinetic]] (1) ·
[[:Category:Selective Serotonin Reuptake Inhibitors (SSRIs)|SSRI]] (1) ·
[[:Category:SGLT2_inhibitors|SGLT2 inhibitor]] (1)
mechanism:
None (8) ·
Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1) ·
The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) ·
TrkB/BDNF'"`UNIQ--ref-00000040-QINU`"' '"`UNIQ--vote-00000041-QINU`"' (1) ·
'"`UNIQ--vote-00000073-QINU`"' The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect'"`UNIQ--ref-00000074-QINU`"'. (1)
uses:
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) ·
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) ·
Major depressive disorder in adults (FDA-approved 2011) (1) ·
'"`UNIQ--vote-00000042-QINU`"', '"`UNIQ--vote-00000043-QINU`"', '"`UNIQ--vote-00000044-QINU`"' (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) ·
'"`UNIQ--vote-00000075-QINU`"', '"`UNIQ--vote-00000076-QINU`"', '"`UNIQ--vote-00000077-QINU`"' (1) ·
'"`UNIQ--vote-0000044C-QINU`"', '"`UNIQ--vote-0000044D-QINU`"', '"`UNIQ--vote-0000044E-QINU`"', '"`UNIQ--vote-0000044F-QINU`"' (1) ·
'"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"' (1) ·
'"`UNIQ--vote-0000056B-QINU`"' (1) ·
'"`UNIQ--vote-0000059D-QINU`"' (1) ·
'"`UNIQ--vote-000005D0-QINU`"', '"`UNIQ--vote-000005D1-QINU`"', '"`UNIQ--vote-000005D2-QINU`"' (1) ·
'"`UNIQ--vote-00000B81-QINU`"', '"`UNIQ--vote-00000B82-QINU`"', '"`UNIQ--vote-00000B83-QINU`"' (1) ·
'"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1) ·
'"`UNIQ--vote-00000EF4-QINU`"', '"`UNIQ--vote-00000EF5-QINU`"', '"`UNIQ--vote-00000EF6-QINU`"', '"`UNIQ--vote-00000EF7-QINU`"', '"`UNIQ--vote-00000EF8-QINU`"' (1)
starting dose:
0.25 mg (1) ·
1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) ·
10 mg (1) ·
10 mg PO once daily in the morning; 5 mg starting in heart failure (1) ·
10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) ·
10 mg PO once daily, with or without food (1) ·
10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID (1) ·
2.5-5 mg PO once daily; titrate to 10 mg/d (1) ·
20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed (1) ·
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) ·
25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1) ·
5 mg daily (1) ·
5 mg PO at bedtime; may increase to 10 mg if inadequate (1) ·
5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1)
preparations:
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
1, 2, 5 mg caps (1) ·
10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist) (1) ·
10 mg, 20 mg, 40 mg caps (1) ·
10 mg, 20 mg, 40 mg tablets (1) ·
2.5, 5, 10 mg tablets; 1 mg/mL oral suspension (1) ·
2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) ·
2.5, 5, 10, 20 mg tabs (1) ·
25 mg, 50 mg tablets (1) ·
25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) ·
5 mg, 10 mg tablets (2) ·
5, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL IV; 15 mg/spray intranasal (1) ·
5, 20, 40 mg tablets (1)
fda max: (Click arrow to add another value)
routes:
onset:
None (1) ·
1–2 h (1) ·
30-60 min (immediate-release); 1-2 h (extended-release) (1) ·
30–90 min (1) ·
4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) ·
BP effect 1 hour; max at 4-6 hours (1) ·
BP effect 1-2 weeks; max at 2-3 weeks (1) ·
BP effect within 24 hours; full effect at 1-2 weeks (long half-life) (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) ·
IV/IM 1-3 minutes; PO 30-60 minutes (1) ·
LDL lowering within 2 weeks (1) ·
Symptom improvement within weeks (1) ·
~30 min (2)
duration:
halflife:
11-13 h (immediate-release); 11-16 h (extended-release) (1) ·
1–4 days (7–15 days for norfluoxetine) (1) ·
2–3 h (1) ·
30-50 hours'"`UNIQ--ref-00000078-QINU`"' (1) ·
5-6 hours'"`UNIQ--ref-00000EF9-QINU`"' (1) ·
~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) ·
~11 hours (enalaprilat, the active metabolite)'"`UNIQ--ref-00000B84-QINU`"' (1) ·
~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1) ·
~13 hours'"`UNIQ--ref-0000056C-QINU`"' (1) ·
~17-19 hours (longer than daridorexant) (1) ·
~22 hours (parent + active glucuronide)'"`UNIQ--ref-00000450-QINU`"' (1) ·
~25 hours (1) ·
~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1) ·
~8 hours (shorter than suvorexant and lemborexant) (1)
bioavailability:
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) ·
64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' (1) ·
70–90% (oral) (1) ·
80-90% oral (1) ·
Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"' (1) ·
~12% (extensive metabolizers); ~96% (poor metabolizers) (1) ·
~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' (1) ·
~44% (1) ·
~60% (1) ·
~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1) ·
~62% (1) ·
~72% (with food); much lower fasting (~36%) (1) ·
~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1) ·
~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"' (1)
pregnancy:
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-0000056E-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1) ·
Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category C (2) ·
Category C'"`UNIQ--ref-00000045-QINU`"' (1) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; avoid (2) ·
Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; generally avoided particularly in combination with statin.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh benefits/risks (1) ·
Widely used for hyperemesis gravidarum; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
Rx (1) ·
Rx, Schedule IV (US) (2) ·
Rx-only in US (2) ·
Schedule IV (US) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (7) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for '''tardive dyskinesia''' (irreversible movement disorder), driving the 12-week chronic-use limit'"`UNIQ--ref-00000EFB-QINU`"' (1)
Showing below up to 14 results in range #1 to #14.